PEMH

Precision Medicine and Health (PEMH) is a high-tech biotechnology company specializing in the development and commercialization of advanced diagnostic solutions for oncology. The company focuses on liquid biopsy technologies, utilizing next-generation sequencing (NGS) to detect circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) for early cancer screening, treatment monitoring, and minimal residual disease (MRD) detection. PEMH provides a comprehensive suite of genomic testing services designed to guide personalized therapy and improve patient outcomes in various solid tumors. Headquartered in Shenzhen, China, the company operates state-of-the-art laboratories and maintains partnerships with clinical institutions to integrate precision medicine into routine oncology care.